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Abstract
Health commodity supply chains are vital to a well-functioning health system and 
advancing national and regional health security goals. This study describes impacts of 
the COVID-19 pandemic on these chains, learnings from it and the challenges faced 
by countries. It also provides futuristic strategic recommendations for the building of 
the supply chain to manage the impacts and guide pandemic responsiveness. We used 
the PRISMA guideline for systematic review to collate relevant information from both 
published and unpublished literature. Out of 622 screened records, 38 were included 
in the review. Major impacts were innovation, collaboration, increased technology, 
research and development, increased prices and shortage of health products, deple-
tion of supply chain personnel. Challenges were lack of visibility, coordination, resil-
ience and strategy for pandemics, potential substandard medicines epidemic, travel 
restrictions and inadequate scientific knowledge. The studies recommended increased 
local production and resilience of supply chains. The pandemic disrupted national 
and international supply chain systems of medical devices, essential medicines and 
pharmaceutical products due to border closures, transportation and international 
trade restrictions. It however exposed hidden potentials in Sub-Saharan Africa. There 
is need to develop supply chain strategy for emergencies, increase local production 
and talent pool for supply chain management particularly in Africa.
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1. Introduction
The COVID-19 pandemic has escalated into the largest health crisis of the 21st 
Century. According to the COVID-19 situation dashboard of the World Health 
Organization (WHO), the virus has infected more than 117,132,788 people worldwide 
to date, and has also killed over 2,600,839 [1]. Epidemiological projections show 
that the outbreak overwhelmed even well-developed healthcare systems [2]. Many 
countries have thus imposed pandemic suppression measures such as lockdowns and 
community quarantines in an effort to stem the progress of the pandemic [3].
Health commodity supply chains are a critical element of a well-functioning 
health system and a vital input to advancing national and regional health secu-
rity goals. Strong medicine and health commodity supply chains improve health 
outcomes and build trust in health systems. Robust supply chains provide critical 
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vaccines, medicines, diagnostics, and other essential health supplies to support 
communicable disease prevention, control, and response activities [4]. A public 
health supply chain is a network of interconnected organizations or actors that 
ensures the availability of health commodities to people who need them. Essentially 
there are four parts to a supply chain; product manufacturers or the suppliers, 
distributors, service providers (hospitals, pharmacies, retail medicine sellers) and 
finally the customers or patients [5].
The coronavirus pandemic is having a clear impact on the supply chains of 
virtually all manufacturers, retailers, and wholesalers. As the world attempts to 
navigate through this difficult time, most companies are struggling to maintain a 
steady flow of required goods and services. Whether it is frozen foods and grocery 
items, or ventilators and masks, medicines or even the services clinic visits etc), the 
supply chain has been facing multiple obstacles [6]. This disruption is mainly due 
to COVID 19 pandemic, emanating from China being the second largest economy 
in the world and the major supplier of inputs for manufacturing companies around 
the world. Majority of the original equipment manufacturers in China have stopped 
production [7]. At present, most of the production capacity of these drugs and 
chemical precursors are in the United States, China and India. Global supply chains 
have been disrupted due to loss of labor and raw material inputs, creating ripple 
effects that cross national boundaries [3].
This chapter describes the impacts of the pandemic on public health supply 
chain, challenges that countries are facing, learnings from the pandemic and 
provides futuristic strategic recommendations for the building and rebuilding of 
the supply chains to manage the impact of the pandemic and guide responsiveness 
towards future pandemics.
2. Data collection process
This chapter is an outcome of a systematic review done by using Purdue librar-
ies online access and e-resources centre ‘All Databases” search tool. The search was 
conducted from June to August, 2020 using the PRISMA checklist. We screened 622 
records and reviewed 31 peer reviewed publications and 7 unpublished papers from 
across the countries.
Literature search was done using keywords like “impact of COVID-19”, “effects 
of COVID-19”, “supply chain and COVID-19”, “health impacts of COVID-19”, 
“global and public health supply chain during pandemics”, “public health and sup-
ply chain”, and “impact of outbreaks” on databases like Pubmed, ProQuest, Google 
Scholar, Web of Science, Science Direct (Elsevier). We have excluded literatures 
that did not report challenges, effect or impact of COVID-19 on health supply chain 
and as well those not reported in English.
Figure 1 shows the flow chart of this review.
After careful review of the articles, 38 out of 622 screened publications were 
selected for inclusion in this study. Extracted data were analyzed and sectioned into 
positive impact, negative impact, challenges, learnings and recommendations.
All the 38 studies included in the review were conducted between February 
and August, 2020. Majority of the studies reviewed were conducted globally 
[8], in Africa [9], Asia [2] and United States [5]. A survey published on March 
28 by the Chartered Institute of Procurement and Supply found that 86% of 
supply chains are impacted by the COVID-19 pandemic while another study by 
the Institute for Supply Management found that between early March and late 
March, 2020, the number of companies experiencing supply chain impact rose 
from 80 to 95% [9].
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2.1 Outcome of systematic review
Our review revealed the following:
2.1.1 Positive impacts
While Covid-19 has been blamed for economic downturns, it has shifted 
organizational focus towards a sustainable supply chain [6]. Other positive impacts 
include:
1. Creativity and Flexibility among Companies and Countries. Due to the impact 
of COVID-19, many companies around the world started to re-purpose or re-
adjust their production, with many brewing companies and distilleries pro-
ducing hand-sanitizers, fashion companies producing masks and automotive 
companies looking to produce ventilators. Some governments and businesses 
developed a variety of innovative prevention measures such as drive-through 
testing kits and products that can be utilized all over the world. Countries that 
have never produced surgical masks, gloves, sanitizers, or ventilators turned to 
domestic production [7, 10–13].
2. Increased Availability and Utilization of Technology and Innovation in the 
Health Sector:
Figure 1. 
Flow of information through the different phases of the review.
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• Technology driven health services which was largely considered a novelty 
or luxury, now has the opportunity to demonstrate real value as traditional 
healthcare services become overwhelmed by patient load demands [7, 14].
• Some organizations were able to quickly mobilize by leveraging existing 
tools for source-code dissemination, accelerating innovation and targeted 
problem-solving. Notably, the COVID-19 emergency has highlighted the 
power of the Maker community to make a real and immediate impact [13].
3. Diversification of suppliers and logistics models:
• The pandemic has thrown up opportunities for entrepreneurs to take 
advantage of the need for sourcing raw materials along more efficient 
commodity routes and methods such as railways, increase in dual sourc-
ing of key components and a preference for larger, more financially stable 
suppliers with multiple manufacturing sites [14, 15].
• Companies that operate regularly in the supply chain should expect to see 
the emergence of stronger, more conservatively financed, multi-site sup-
pliers as a long-term outcome of the pandemic [14].
4. Increased Capacity in Research and Development: As the world manages to 
contain Covid-19 outbreak, various countries and firms are focusing on find-
ing a vaccine, developing protocol to treat infected patients, adopting capabili-
ties which ensure the integrity of the processes and the quality of the products 
and creating a safe working environment for employees [6, 7, 13].
2.1.2 Negative impacts
Unlike other disruption risks, the epidemic outbreaks start small but scale fast and 
disperse over many geographic regions causing simultaneous disruptions in supply, 
demand, and logistics infrastructure [16]. A report published on 21 February 2020, 
indicated that 94% of the companies listed in the Fortune 1000 list were already fac-
ing SC disruptions due to the COVID-19 [17]. Other negative impacts include:
1. Shortage in essential and non-essential medicines, raw materials, medical and 
pharmaceuticals products: As a result of the surge in the pandemic which led 
to the inevitable lock down of the economy across affected countries, there has 
been a noticeable decrease in production and exportation of equipment, raw 
materials, as well as finished products across different countries [6]. Produc-
tion supply shortages, transport interruption and the virus containment 
measures taken by the government was limiting market access, hampering 
manufacturing activities and nudging the economy towards an inflationary 
recession which is adversely affecting the manufacturing sector, including that 
of health products production [7, 16, 18–20]. It has certainly surprised many 
to discover just how much western countries (in which shortages are particu-
larly prevalent) rely upon global supply chains to obtain medical supplies 
from China and low-cost economies [21]. However, these networks have poor 
resilience to global disruptions, with nearly 35% of manufacturers reporting 
disturbances due to the global Corona virus pandemic [8, 11, 22]. Given the 
expected increase in COVID-19 cases and global competition for sourcing PPE, 
many medical facilities currently do not have enough stock and/or reliable 
resources to meet the anticipated demand [10].
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2. Congestion of cargo terminals and delays in transportation of food and health 
commodities due to travel ban and movement restrictions: The severe spread of 
the virus into Europe and the United States has blocked the movement of the 
products and materials worldwide [8]. Many manufacturers and service provid-
ers experienced disruptions as more than $100 million worth of goods were stuck 
in China during the China lockdown [7]. For many countries and firms, the 
inability to respond to the Covid-19 outbreak lies in its transportation services 
[23]. The world’s largest 1,000 companies had over 12,000 factories, warehouses 
and operations in quarantined regions in early March, 2020 [19]. If cargo does 
not flow, within days, there will be no space in the terminals to discharge other 
cargo and some of the cargo waiting to be discharged includes food and medi-
cine [7].
3. Depletion of human resource for supply chain: COVID-19 has cost hundreds 
of thousands of human lives globally including healthcare professionals, and 
exposed the weaknesses of national health systems worldwide [12]. Global 
supply chains have been disrupted due to loss of labor and raw material inputs, 
creating ripple effects that cross national boundaries [3].
4. Some big multi- nationals have left themselves dangerously exposed to supply-
chain risk owing to strategies designed to bring down their costs [24].
5. Reduced access to medicines due to increase in prices of medicines and move-
ment restrictions: In Nigeria, the lockdown which was accompanied with the 
closure of borders and travel ban across states led to a significant drop in the 
quantity of essential medicines in the health facilities with a consequent in-
crease in the prices of medicines, hand sanitizers, face masks, personal protec-
tive equipment, and other medical equipment used for providing health care, 
making it difficult for consumers to get the medicines they need [25].
6. Reduced patronage to small scale suppliers: An increase in dual sourcing of key 
components and a preference for larger, more financially stable suppliers with 
multiple manufacturing sites presents new challenges for smaller and more 
leveraged companies, regardless of their expertise [14, 15].
2.1.3 Challenges
The COVID-19 pandemic has triggered a number of challenges that have led 
to shortages and price hikes, and could potentially fuel an epidemic of fake and 
substandard medicines [26]. Findings from the reviewed literature reported the 
following challenges:
1. There is lack of visibility, collaboration and coordination of real demand and sup-
ply [7]. A survey with over 700 respondents conducted by Bass ware found that 
60% of responding procurement managers experience a lack of transparency in 
their supply chain [9]. Absence of supply chain strategy for pandemics: Decision-
making is executed under epistemic and stochastic uncertainty [27, 28].
2. Some supply chain disruption are not included in regular supplier perfor-
mance metrics and such, unplanned for. Most supply chains are still based on 
reactive or transactional model, therefore, it could take several days or month 
to adjust supply chains during pandemics [7]. It has become extremely chal-
lenging to continue the operations of supply chains as the operations of some 
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parts of the supply chain in some firms has stopped with little or no alterna-
tives during disruption [7, 29]. ISM also found that 44% of respondents to 
its survey did not have plans in place to cope with supply disruptions from 
China [9].
3. It is a great challenge to provide medical supplies (such as masks and protec-
tive clothing etc.) and equipment (for checking, testing, and monitoring the 
disease etc.) to meet the needs of treatment, protection, and control [7]. In a 
pandemic situation, the demand of the essential products increases expres-
sively; on the other hand, the supply of the raw materials decreases consider-
ably with a constraint of production capacity. These dual disruptions impact 
the production process suddenly, and the process can collapse without imme-
diate and necessary actions [8, 16, 30]. Limitation on international trade and 
travel; The ban on the international travel during this pandemic may pose a 
serious challenge to the healthcare system in Nigeria and across Africa because 
of heavy reliance of Nigeria and other developing countries on importation 
of medicines, API and other needed resources for drug manufacturing from 
other countries [31]. Due to severe disruptions (e.g., manufacturers closed 
or partially closed, air- ports operating with harsh restrictions, shortages 
of medical equipment and supplies) recorded, a good number of industries 
including health commodity manufacturers may experience ripple effects 
[17, 29].
4. Cost and legal issues: Another challenging part is keeping cost under control 
which includes higher production costs, shipping costs and agreed costs of 
pending orders. A legal issue related to disagreeing the agreed cost as a Force 
Majeure clause or not, poses legal challenge for every company [32].
5. Wrong supply chain success function shift, which focuses on just cost savings 
and not revenue-assurance or sustainability [7]. A lot of the resilience chal-
lenges have arisen from a cost obsession and short-term cost focus in supply 
chain management [9].
6. Once effective pharmaceutical treatments are found, there will be the major 
engineering challenge of ramping up production at a rate that matches the 
pandemic [27]. Planning will be hindered by the lack of solid scientific knowl-
edge about COVID-19 and inadequate literature on pharmaceutical supply 
chain (PSC) network design in the disastrous situations and other uncertain-
ties (current literature on disruption recovery strategies and modeling during 
pandemics is mostly limited to humanitarian logistics) which make demand 
projections highly uncertain [16, 22, 27].
7. Limited supply chain talents in Africa [28].
2.1.4 Learnings
1. Social Resilience among Supply Chain Partners, Healthcare professionals and 
Patients: Most supply chains are transactional in nature but transactional sup-
ply chain will not be beneficial during and post Covid-19 [6] Thus;
• It is critical to prepare health care professionals to build resilience in their 
interactions with patients and other stakeholders [12]
7
Global Impact of COVID-19 Pandemic on Public Health Supply Chains
DOI: http://dx.doi.org/10.5772/intechopen.97454
• By developing a culture of collaboration across its supply network, a firm 
can develop trust among supply chain partners that can help in data-
sharing and joint problem-solving [6]
• Covid-19 has forced companies to lay greater emphasis on the environ-
mental and social aspects of public health supply chain and not just the 
economical aspect [6, 33]
2. Inflexibility of Supply Chains: Most firms follow strict rules for their supply 
chain such as; specific number of days for distribution, specific production 
time, delivery rules, etc. These responses have proved to be inadequate during 
the crisis. Thus, reacting to the Covid-19 requires flexibility in the supply chain 
and the overall ecosystem of a firm;
• The central learning from Covid-19 is to diversify production, sourcing, and 
logistics whenever and however required such that external shocks cannot 
disrupt the supply chain [6].
• We also found evidence that centralized procurement and tendering can 
achieve direct cost savings, while supply chain management program can 
reduce drug stock outs and increase drug availability for populations [34].
3. The Decoupling from China’s Supply Chains: COVID-19 has accelerated two 
powerful trends for the future, the decoupling from China’s supply chains and 
the relocation of strategic manufacturing operations out of China [12]. A study 
by corporate data analytics firm, Dun & Bradstreet, reported that 51,000 
companies around the world have one or more direct suppliers in Wuhan and 
at least 5 million companies around the world have one or more tier-two sup-
pliers in the Wuhan region, where COVID-19 originated [18]. In US, there’s 
been bipartisan support for legislation that would study the current medical 
equipment supply chain and develop an action plan to potentially address the 
country’s dependence on foreign-made products [21].
4. Strategies to deal with Major Outbreaks
• Designing an appropriate pharmaceutical supply chain network for pre-
positioning and distributing drugs at post-disaster plays an important role 
in decreasing the response time and the number of casualties.
• Pre-positioning of emergency supplies belongs to the preparedness phase 
of a disaster that brings about some advantages for the Humanitarian 
organizations [22].
5. Analysis of the Italian production network has found that sectors are both 
highly connected and asymmetrically connected. Hence, a local shock due to 
lockdown policy propagates through the whole economy and generates a size-
able global disturbance. This confirms the importance of value chain analysis 
in investigating how the economy adjusts to dislocation and destruction of 
parts of its productive capacity [35].
6. The current impact of the COVID-19 outbreak on the manufacturing firms 
is already very severe and medium-to-long-term impacts are predicted to be 
Evidence-Based Approaches to Effectively Respond to Public Health Emergencies
8
higher than that of any other previous major outbreaks such as 2003 SARS and 
2009 H1N1 [21, 36–38].
2.1.5 Recommendations
Key levers for de-risking the supply chain include the need to balance global 
sourcing with near shore and local sourcing, the adoption of multiple sources and a 
greater utilization of information technology to drive more complete and immedi-
ate information availability. Talent management in supply chain management needs 
to promote a focus not just on costs, but also on resilience as well as on learning 
from current events to improve decision-making [10, 30]. Findings from the 
reviewed literature reported the following recommendations:
1. Strengthen Local Manufacturing Capacity and Fortify local supply chain: 
The global scientific community has been galvanized into action in a frantic 
search for a cure for COVID-19. Greater collaboration between governments 
and industries will be needed to ensure minimum disruption in global supply 
chains Firms also need to collaborate with multiple stakeholders and be more 
strategic in their approach to supply chain management. Companies have to 
come up with alternative means of raw materials sourcing and identify other 
modes of cost benefit transportation. This will also involve identifying urgent 
research and development challenges for pharmaceutical supply chains. 
There should be increased R & D by local universities who should create 
specialized post-graduate schools that focus on research, while also recruit-
ing and training fresh lecturers who focus on research and product/process 
development to grow the domestic manufacturing sector [6, 12, 15, 16, 22, 28, 
29, 32, 39].
2. Technological Augmentation and Utilization: Studies have recommended new 
supply chain technologies that dramatically improve collaboration, visibil-
ity, agility and optimization across the end-to-end supply chain, understand 
complexities and support companies’ ability to resist such shocks from impact 
of any pandemics or rare events. Block chain systems can assist in keeping the 
data needed for recoveries such as information and data for production capac-
ity, human resources requirements, information of supplier capacities, and 
emergency suppliers [6, 17, 30, 32, 38, 40].
3. Policymakers and program managers should examine the root causes of inef-
ficiencies in pharmaceutical supply chain and procurement processes in order 
to determine how best to improve health systems performance in their specific 
contexts. In addition they should consider the root causes of programmatic 
challenges to purchasing and distributing health products in their context 
and identify specific interventions that can strengthen these processes. As the 
evolution and implications of the COVID-19 crisis are still unfolding, we posit 
that exploring the experiences and strategic responses of Asian countries may 
shed some useful light on ways to combat COVID-19 for the policymakers and 
suuply chain managers in the rest of the world [12, 34].
4. Development and Assessment of supply chain strategies: Optimal supply chain 
planning taking into account agility, resilience and sustainability are impor-
tant. The negative impact of the pandemic has fostered the need for develop-
ment and implementation of health supply chain strategy. The next-generation 
supply chain needs a significant change in outlook. Based on our analysis, we 
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recommend firms adopt a forward looking approach. These forward-looking 
strategies must comprise of multiple facets of the supply chain including 
people, processes, and technology.
Devoting resources for supply network mapping as a risk-mitigation strategy. 
A firm can design its supply network in such a way that it can balance risk and 
operational flexibility, manage supply chain disruptions, and keep supply chain 
agile. Brian Higgins, a principal Supply Chain & Operations Leader of KPMG, 
US has recommended some very pertinent action points for the long term:
• Build agility and speed into your supply chain by creating Micro-
Supply Chains;
• Assess opportunities to diversify the supplier base and identify geographically 
diverse suppliers to onboard in the event of emergency. Consideration should 
be given to dual-sourcing for critical components.
• Move towards a Supplier-Centric approach to procurement, further integrating 
your supply chain with those of your direct suppliers to Original Equipment 
Manufacturers and direct suppliers to Tier-1 and Tier 2 suppliers
• Look to develop more collaborative relationships with critical suppliers in other 
to build organizational resilience as it is highly unrealistic to completely exit 
the Chinese market because of the supplier ecosystem in the place, however, 
organizations should understand their supply chain more deeply.
A study proposed a framework for operations and supply chain management 
at the times of COVID-19 pandemic spanning six perspectives, i.e., adaptation, 
digitalization, preparedness, recovery, ripple effect, and sustainability.
Assessment of COVID-19-related procurement and supply chain risks and 
life-cycle sustainability assessment of pharmaceutical product systems and 
development of drug allocation strategies under resource or supply constraints 
were recommended [6, 17, 41].
5. Human resource supply chain strategy that includes the selection of the criti-
cal workforce that can handle the turbulence in any environment. The supply 
chain initiatives will require a focused Crisis Management head whose skills 
and responsibility will be to communicate to all stake holders, consolidat-
ing requirements and setting priorities and work on risk mitigating methods 
of supply chain during non-crisis period. This will need scenario planning, 
resource optimization, and efficiency management. There is a greater need for 
a firm to look beyond profitability. Ensuring the well-being of not only a firm’s 
employees but also those employed even with suppliers is critical if a firm 
wants to avoid disruptions in the supply chain [6, 32].
6. Utilize suitable resilience strategies for designing pharmaceutical relief net-
works, employ other types of supply contracts, consider the coordination and 
collaboration of multiple humanitarian organizations in a collaborative setting 
and address the case in which successive disasters may happen. Relief manag-
ers can ensure the high availability level of pre-positioned pharmaceutical 
items by paying attention to their procurement time and shelf-lives. By utiliz-
ing mobile pharmacies the distance between relief shelters and drug supply 
sites can be reduced, and the distribution of drugs to inaccessible areas can be 
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possible. Infectious disease outbreak preparedness strategies should incorpo-
rate primary healthcare services and other health system modalities to cater for 
non– pandemic-related conditions [18, 22].
Suppliers should manage the perception of their readiness to adapt to changing 
situations. Those that demonstrate competence will be rewarded as their customers 
look back in the coming years. Rather than ignore or complain about uncertainty, 
suppliers will be well-served if they can demonstrate plans that show customers 
they can reliably manufacture regardless of societal disruptions. Suppliers also need 
to be dynamic by focusing on multiple best practices explored by other suppliers, 
competitors and ecosystem in order to optimize cost and delivery, improve vis-
ibility across the network, and accelerate reaction times to issues in production and 
delivery [6, 14, 15].
2.2 Discussion and conclusions
The COVID-19 pandemic has impacted global health product supply chains, 
affecting key materials and ingredients, finished health products, logistics, and 
shipping medical devices, essential medicines and pharmaceutical products as 
a result of border closures, international trade restrictions and transportation 
problems [42]. The COVID-19 pandemic clearly shows the lack of resilience in 
supply chains and the impact that disruptions may have on a global network scale as 
individual supply chain connections and nodes fail [41].
As did HIV, the COVID-19 is likely to have profound and long-term conse-
quences on global health care supply chains. The HIV pandemic transformed health 
care supply chains globally and in particular in lower and middle-income countries, 
(LMICs) leading to the mobilization of new financial resources for health care 
products, service delivery, and the creation of international bodies (including The 
Global Fund and PEPFAR) [43].
The short-term effects of COVID-19 on global health care supply chains have 
been severe; factory and border closures, transportation disruption, shifting 
demand, and price increases but it is more important to reflect on what the long-
term consequences will be and how global changes will affect the LMICs. This is 
because LMICs are in their early stages of pharmaceutical development; thus they 
rely on importation of drugs, raw materials and equipment from countries outside 
the region, notably India and China.18 Researchers wonder whether the changes will 
be positive overall or if countries will revert to the same systems that left us unpre-
pared for an international pandemic. This review was unable to find answer to these 
questions. However, crises like pandemics tend to have lasting impacts, and it is 
likely that the short-term disruption of health care supply chains we are seeing will 
result in longer-term structural changes. This highlights the need for policymakers 
to address challenges to large-scale and sustainable drug manufacturing, using the 
COVID-19 situation as a learning opportunity. It is interesting that some companies 
are offering strong technological solutions, which may help them survive and even 
prosper. While the hope is that COVID-19 will increase recognition of the impor-
tance of strong health care supply chains with commensurate investment, there will 
also be pressure on funders to rebuild their own shattered economies. There will be 
pressure to turn inward, certainly over the short term. There may also be opportuni-
ties for alternative financing mechanisms including venture capital [43]. The review 
has noted the fact that disruption does not necessarily mean negative outcomes and 
that it is incumbent on all health supply chains organizations to turn this disruptive 
event into positive change.
The COVID-19 pandemic is a disruption of an unprecedented magnitude, which is 
testing the resilience of global supply chains. The ability for a supply chain’s operators 
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to effectively plan, enabling a means for the supply chain to absorb, recover from, 
and adapt to disruptions of various lengths, impacts, and probabilities, is essential to 
ensuring the supply chain’s function and success. For a supply chain, resilience mea-
sures the ability to prepare for and provide essential functions during a disruption, 
and then to recover from and adapt post-disruption into a form that is better suited to 
the new “present.” Although sustainability, robustness, risk mitigation, leanness, and 
other supply chain management practices are important for business success, supply 
chain resilience is unique in its focus on recovery following a disruptive event [44].
Maintaining the supply chain of pharmaceutical products is not only paramount 
to cover the immediate medical response but will be fundamental to reducing 
disruption of the healthcare delivery system, which requires constant medicines, 
diagnostic tools and vaccines for smooth functioning.
In Nigeria, for example, over 70% of the prescribed medications are produced 
from active pharmaceutical ingredients (API) primarily sourced from firms in 
China and India. Uninterrupted access to medicine is an integral part of healthcare 
systems much needed and essential for the well-being of the population, but the 
COVID-19 pandemic has threatened this [31].
There is need to consider the new digital technologies that have potential to 
improve the ripple effect control in cases of epidemic outbreaks. Making innova-
tions and data work for the supply chain resilience in crisis times, understanding 
and progressing the research of how these technologies can be used boost supply 
chains resilience, are important future research areas with a particular focus on data 
analytics, artificial intelligence, and machine learning [45].
There is minimal risk of bias in this study as articles were merely reviewed as 
presented and reviewers were not privy to the original data of the individual studies. 
Reviewers were also not interested in the outcome of the review but aimed at provid-
ing recommendations to country supply chains for the benefit of public health. None 
of the reviewers is a publisher of any of the articles reviewed. The review is limited 
to the competences of the reviewers in interpreting the results and to the fact that 
the coverage of included articles was flexible and neither restricted the review to 
articles conducted in homogenous settings nor compared their findings.
This study buttresses the need to devise and institute clear strategies on supply 
chain management in country and regional emergency responses, promotion of 
local manufacturing of medicines and other health products to reduce the extensive 
dependency on importation from international markets and increase the talent pool 
of supply chain management especially in Africa.
The review concluded that many manufacturers and service providers in some 
countries are already experiencing severe shortage of essential and non-essential 
raw materials including medical and pharmaceutical products, in addition to inter-
mediate inputs, due to the COVID-19 pandemic and it’s consequent border closures, 
trade restrictions among nations, and transportation problems. The COVID-19 pan-
demic however exposed some hidden potentials in many countries especially in Sub 
Saharan African. There is need for health supply chain resilience through develop-
ment of a reliable supply chain strategy for pandemics and other such emergencies.
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